Head-to-head evidence
Abemaciclib vs Dalpiciclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Abemaciclib · Verzenio
Marketed by Eli Lilly
NCT02102490 · Phase 2 · completed
This was a single-arm, open-label study of 132 participants with no placebo or active comparator and no randomization or blinding. Its primary endpoint was the clinical tumor-response rate, reported as 19.7%, but the uncontrolled design makes the result descriptive rather than comparative evidence.
Next expected readout: December 2026 · NCT05307705 (registry estimate)
Dalpiciclib
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06009627 · Phase 2/3 · completed
The trial randomized 119 participants to an active chemotherapy comparator and used investigator masking, but it was not double-blind. Its primary endpoint was objective tumor response rate, and no primary endpoint results or statistical comparison have been posted, so the outcome cannot be judged as met or missed.
Next expected readout: October 2026 · NCT04842617 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abemaciclib's landscape · Dalpiciclib's landscape